Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of dasatinib in treating patients
with solid tumors or lymphomas that are metastatic or cannot be removed by surgery. Dasatinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.